FierceBiotech 2026-03-02 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech 2026-02-28 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech 2026-02-27 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
FierceBiotech 2026-02-27 Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
FierceBiotech 2026-02-27 FDA slams ExThera with warning letter over controversial blood filter device
FierceBiotech 2026-02-27 As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
FierceBiotech 2026-02-27 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
FierceBiotech 2026-02-26 Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
FierceBiotech 2026-02-26 Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
FierceBiotech 2026-02-26 Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
FierceBiotech 2026-02-26 Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
FierceBiotech 2026-02-26 Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
FierceBiotech 2026-02-26 Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
FierceBiotech 2026-02-26 Accent halts solid tumor trial over adverse events, pivots to other lead cancer program